2017 No. 631
The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017
Made
Coming into force
To be laid before Parliament
The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 19711.
In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.
Citation, commencement and extent1
1
These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.
2
These Regulations extend to England and Wales and Scotland.
Amendment of the Misuse of Drugs Regulations 2001
2
The Misuse of Drugs Regulations 20012 are amended as follows.
3
In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16 , 18, 19, 20, 23, 26 and 27)—
a
before “Bufotenine” insert—
Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)
N-Benzyl-ethylphenidate
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
b
after “Cathinone” insert—
4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
c
after “Concentrate of poppy-straw” insert—
Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
3,4-Dichloroethylphenidate
3,4-Dichloromethylphenidate (3,4-DCMP)
Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
d
after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—
Ethylnaphthidate
Ethylphenidate
e
after “Eticyclidine” insert—
Etizolam
f
after “Etryptamine” insert—
Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
4-Fluoroethylphenidate
4-Fluoromethylphenidate
Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
g
after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol” insert—
3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Isopropylphenidate (IPP or IPPD)
h
after “Lysergide and other N-alkyl derivatives of lysergamide” insert—
Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
i
after “Methcathinone” insert—
4-Methylmethylphenidate
Methylmorphenate
Methylnaphthidate (HDMP-28)
Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)
Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
Propylphenidate
j
after “Psilocin” insert—
Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
k
after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)
(This note is not part of the Regulations)